SOURCE: Amexdrug Corporation

March 21, 2007 12:28 ET

Amexdrug Corp. Unveils New Product Line

BEVERLY HILLS, CA -- (MARKET WIRE) -- March 21, 2007 -- Amexdrug Corporation (OTCBB: AXRX) today announced that it has completed formulation and market analysis, and has moved on to the initial production phase of its new line of five over-the-counter products aimed at fungal infections, brittle nails, as well as a topical analgesic. These over-the-counter natural products will be manufactured using all FDA-approved ingredients through Amexdrug's subsidiary Dermagen, Inc., and will be sold and marketed through another Amexdrug subsidiary, BioRX Pharmaceuticals.

The preliminary stage of the marketing plan calls for the products to be sold and marketed through chain drug stores, natural food and health stores, and sports chain stores across the United States, with subsequent sales and marketing to expand internationally. Company research indicates that between 30 and 40 million Americans suffer from some type of persistent fungal infection and/or brittle and unsightly nails, and more than 1 billion people suffer from fungal infections worldwide. In addition, the U.S. market for over-the-counter (OTC) anti-infective products surpassed $2 billion in 2005. Finally, the U.S. market for antiarthritic drugs and analgesics has grown from $9.1 billion in 2000 to $13.5 billion in 2004. As a consequence, Amexdrug is extremely confident that there is more than sufficient market demand for these new products.

According to a company spokesperson, "Our market research has shown evidence of significant demand sectors, making this one of the Company's more anticipated product releases. Based on our research, we are confident that these latest offerings will have an immediate positive impact on revenues once we unveil them in mid-April of this year. Utilizing a review of competitive pricing structures and our initial internal cost analysis, the Company strongly believes that sales of these products will provide exceptional margins, and so we are understandably eagerly awaiting their imminent arrival on the marketplace."

About Amexdrug Corporation:

Amexdrug Corporation is a vertically integrated company operating in the highly lucrative pharmaceutical and cosmeceutical industries. Along with its subsidiaries Dermagen, Inc. and BioRX Pharmaceuticals, Amexdrug is engaged in the research and development, marketing, production and sale of over-the-counter (OTC) pharmaceuticals and cosmetics as well as the distribution of prescription and over-the-counter drugs. The Company has advanced manufacturing facilities as well as an extensive distribution network, allowing Amexdrug to integrate various phases of operations into one efficient business entity. For more about Amexdrug, go to our website at www.amexdrug.com.

Safe Harbor Statement:

Except for historical information contained herein, the matters set forth above may be forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ from those in the forward-looking statements. Words such as "anticipate," "believe," "estimate," "expect," "intend" and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the current beliefs of management, as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors such as the level of business and consumer spending, the amount of sales of the Company's products, the competitive environment within the industry, the ability of the Company to continue to expand its operations, the level of costs incurred in connection with the Company's expansion efforts, economic conditions in the industry and the financial strength of the Company's customers and suppliers. The Company does not undertake any obligation to update such forward-looking statements. Investors are also directed to consider all other risks and uncertainties.

Contact Information


  • Contact:

    tel: 310-855-0475
    add: 369 S. Doheny dr#326, Beverly Hills, Ca. 90211